Alterations of skin innate immunity in lymphedematous limbs: Correlations with opportunistic diseases

Clinics in Dermatology

Volumn 32, Issue 5, 2014, Pages 592-598

  Baroni, Adone ^a   Buommino, Elisabetta ^a   Piccolo, Vincenzo ^a   Chessa, Marco Adriano ^a   Russo, Teresa ^a   Cozza, Valentina ^a   Ruocco, Vincenzo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; DESMOGLEIN 1; DESMOGLEIN 3; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; SURVIVIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; INNATE IMMUNITY; KERATINOCYTE; LYMPHEDEMA; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN INNATE IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LIMB; SKIN;

EXTREMITIES; HUMANS; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; LYMPHEDEMA; SKIN;

EID: 84906350309     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2014.04.006     Document Type: Note

References (35)

1. Ruocco V., Schwartz R.A., Ruocco E. Lymphedema: An immunologically vulnerable site for development of neoplasms. J Am Acad Dermatol 2002, 47:124-127.
2. Baroni A., Ruocco V., Di Maio R., Nuzzo T., Del Vecchio M., Ruocco E. Papillomatosis cutis arising on an immuno-compromised district due to paraplegia. Br J Dermatol 2010, 163:646-648.
3. Baroni A., Brunetti G., Ruocco E. Coexistence of malignancy (skin cancer) and immune disorder (discoid lupus erythematosus) on a burn scar: A concrete example of 'immunocompromised district'. Br J Dermatol 2011, 164:673-675.
4. Ruocco V., Brunetti G., Puca R.V., Ruocco E. The immunocompromised district: A unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol Venereol 2009, 23:1364-1373.
5. Baroni A., Piccolo V., Russo T., Ruocco V. Recurrent blistering of the fingertips as a sign of carpal tunnel syndrome: An effect of nerve compression. Arch Dermatol 2012, 148:545-546.
6. Piccolo V., Russo T., Baroni A. Unilateral bullous pemphigoid in hemiplegic patients: An instance of immunocompromised district. J Dermatol 2013, 40:64-65.
7. Baroni A., Orlando M., Donnarumma G., et al. Toll-like receptor 2 (TLR2) mediates intracellular signalling in human keratinocytes in response to Malassezia furfur. Arch Dermatol Res 2006, 297:280-288.
8. Boyce S.T., Ham R.G. Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. J Invest Dermatol 1983, 81:33-40.
9. Chen Y.J., Chang J.T., Lee L., et al. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 2007, 26:467-476.
10. Dallaglio K., Marconi A., Pincelli C. Survivin: A dual player in healthy and diseased skin. J Invest Dermatol 2012, 132:18-27.
11. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
12. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002, 111:927-930.
13. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
14. Hazlett L., Wu M. Defensins in innate immunity. Cell Tissue Res 2011, 343:175-188.
15. Ronit A., Salem M., Hartling H.J., et al. Dysregulation of toll-like receptor (TLR) 2 expression on monocytes and upregulation of the frequency of T cells expressing TLR2 in patients with chronic hepatitis C virus infection. APMIS 2013, 121:437-446.
16. Pimentel-Nunes P., Afonso L., Lopes P., et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 2011, 17:677-683.
17. Tye H., Kennedy C.L., Najdovska M., et al. STAT3-Driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012, 22:466-478.
18. Verma C., Seebah S., Low S.M., et al. Defensins: Antimicrobial peptides for therapeutic development. Biotechnol J 2007, 2:1353-1359.
19. Elsbach P. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses?. J Clin Invest 2003, 111:1643-1645.
20. Niyonsaba F., Ushio H., Nakano N., et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocytes migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007, 127:594-604.
21. McDermott A.M., Redfern R.L., Zhang B. Human beta-defensin 2 is up-regulated during re-epithelialization of the cornea. Curr Eye Res 2001, 22:64-67.
22. Hollox E.J., Huffmeier U., Zeeuwen P.L., et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008, 40:23-25.
23. Sawaki K., Mizukawa N., Yamaai T., Yoshimoto T., Nakano M., Sugahara T. High concentration of beta-defensin-2 in oral squamous cell carcinoma. Anticancer Res 2002, 22:2103-2107.
24. Gambichler T., Skrygan M., Huyn J., et al. Pattern of mRNA expression of β-defensins in basal cell carcinoma. BMC Cancer 2006, 6:163.
25. Winter J., Pantelis A., Reich R., et al. Human beta-defensin-1, -2, and -3 exhibit opposite effects on oral squamous cell carcinoma cell proliferation. Cancer Invest 2011, 29:196-201.
26. Clausen M.L., Jungersted J.M., Andersen P.S., Slotved H.C., Krogfelt K.A., Agner T. Human beta-defensin-2 as a marker for disease severity and skin barrier properties in Atopic Dermatitis. Br J Dermatol 2013, 10.1111/bjd.12419.
27. Hau C.S., Kanda N., Noda S., et al. Visfatin enhances the production of cathelicidin antimicrobial peptide, human β-defensin-2, human β-defensin-3, and S100 A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin. Am J Pathol 2013, 182:1705-1717.
28. Abiko Y., Suraweera A.K., Nishimura M., et al. Differential expression of human beta-defensin 2 in keratinized and non-keratinized oral epithelial lesions; immunohistochemistry and in situ hybridization. Virchows Arch 2001, 438:248-253.
29. Marzano A.V., Cugno M., Trevisan V., et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010, 162:100-107.
30. Hofmann U.B., Eggert A.A., Blass K., Bröcker E.B., Becker J.C. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003, 63:8221-8225.
31. Redondo P., Lloret P., Idoate M., Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 2005, 30:541-545.
32. Shibata Y., Foster L.A., Kurimoto M., et al. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J Immunol 1998, 161:4283-4288.
33. Lippitz B.E. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol 2013, 14:e218-e228.
34. Ding W., Manni M., Stohl L.L., Zhou X.K., Wagner J.A., Granstein R.D. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol 2012, 42:901-911.
35. Reich A., Szepietowski J.C. Vasoactive peptides in the pathogenesis of psoriasis. G Ital Dermatol Venereol 2008, 143:289-298.